KCT0007066尚未招募未知
Evaluation pharmacokinetics and pharmacodynamics of remimazolam during total intravenous anesthesia with remifentanil in patients underwent surgery
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18?(Year) 至 85?(Year)（—）
- 性别
- All
入选标准
- •the patients who undergoing general anesthesia during regular surgery at Busan Paik Hospital, aged 18 to 85 and rated 1 to 3 class by the American Society of Anesthesia classification
排除标准
- •Patients with difficulty in communication, hypersensitivity to benzodiazepine or flumagenyl, neurological disorders (such as cognitive impairment, dementia etc.) that may affect cognitive function, past history within three months or current use of drugs that affect the central nervous system (such as antipsychotics, antidepressants, anti-anxiety drugs, anticonvulsants, etc.), alcohol addiction within two years, a history of alcohol dependence
研究者
相似试验
已完成
不适用
Assessment of pharmacokinetics and pharmacokinetic drug-drug interaction with ketoconazole of the metabolite S 41015 after single oral unlabelled microdoses of S 41015 and i.v. radiolabelled microdoses of [14C]-S 41015, and pharmacokinetics of S 38844 after single oral unlabelled microdose of S 38844 and i.v. radiolabelled microdose of [14C]-S 38844 in healthy male participantshart- en vaatziektencardiovascular diseasesNL-OMON38625Institut de Recherches Internationales Servier I.R.I.S6
进行中（未招募）
不适用
Evaluation of blood drug level profile, effect and safety after repeated administration of a slow release formulation of S-38844 in healthy male volunteersEUCTR2010-020197-42-DEInstitut de Recherches Internationales Servier27
进行中（未招募）
不适用
Evaluation of the reduction in heart rate, of the quantity of drug in the plasma and of the safety after different ascending oral doses of the active substance or a placebo in heart failure patients with a reduction of left ventricular ejection fraction (i.e. thequantity of blood the heart is able to eject in the body at each heart beat).EUCTR2013-003000-39-EEInstitut de Recherches Internationales Servier125
进行中（未招募）
不适用
Evaluation of the reduction in heart rate, of the quantity of drug in the plasma and of the safety after different ascending oral doses of the active substance or a placebo in heart failure patients with a reduction of left ventricular ejection fraction (i.e. thequantity of blood the heart is able to eject in the body at each heart beat).EUCTR2013-003000-39-HUInstitut de Recherches Internationales Servier200
进行中（未招募）
不适用
Evaluation of the reduction in heart rate, of the quantity of drug in the plasma and of the safety after different ascending oral doses of the active substance or a placebo in heart failure patients with a reduction of left ventricular ejection fraction (i.e. thequantity of blood the heart is able to eject in the body at each heart beat).Patients with chronic heart failure and left ventricular systolicdysfunctionMedDRA version: 17.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849EUCTR2013-003000-39-BEInstitut de Recherches Internationales Servier125